Showing 15 posts of 15 posts found.

FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease

March 5, 2021
Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis

Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …

NIHR logo

Roche teams with DH for drug repurposing trial

January 6, 2016
Research and Development DH, NIHR, Off Patent Drugs Bill, Off-Patent Drugs Bill, RoActemra, Roche, drug repurposing, tocilizumab

Roche and the UK Department of Health have launched a trial, to explore whether one of the company’s treatments for …

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

Roche image

Roche buoyed by cancer drug sales

April 22, 2015
Sales and Marketing Actemra, Cancer, Esbriet, Esbriet., MabThera, Q1, Rituxan, RoActemra, Roche, Xolair, avastin, oncology

Pharma’s biggest cancer drugs maker Roche has reported strong sales growth on the back of its oncology portfolio for its …

RoActemra image

RoActemra superior to Humira as single-agent therapy

June 7, 2012
Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA

Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …

RoActemra image

Roche’s RoActemra beats Humira in arthritis study

March 5, 2012
Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis

Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …


NICE gives partial recommendation for RoActemra

December 14, 2011
Sales and Marketing RoActemra, Roche

Roche’s patient access scheme has persuaded NICE to recommend RoActemra in childhood arthritis under certain circumstances. In its final guidance …

NICE recommends RoActemra for early use in arthritis

October 13, 2011
Sales and Marketing NICE, RoActemra

NICE has recommended Roche’s drug RoActemra be used at an earlier stage for some arthritis patients. In draft guidance NICE …

NICE wants more RoActemra data for juvenile idiopathic arthritis

August 9, 2011
Medical Communications NICE, RoActemra, Roche

NICE has requested more evidence from Roche for RoActemra in childhood arthritis. RoActemra (tocilizumab) is being assessed for the treatment …

NICE thumbs up for Roche arthritis drug

July 2, 2010
Sales and Marketing NICE, RoActemra, Roche

NICE has given preliminary approval to Roche’s RoActemra as an additional option for the treatment of moderate to severe rheumatoid …

Rheumatoid arthritis

Roche halts ocrelizumab trials

March 8, 2010
Research and Development RoActemra, ocrelizumab, rheumatoid arthritis

The future of Roche and Biogen Idec’s rheumatoid arthritis drug ocrelizumab has been thrown into doubt after the manufacturers decided …

NICE asks Roche for RoActemra cost data

March 5, 2010
Sales and Marketing RoActemra, Roche

Roche’s attempts to secure NICE approval for rheumatoid arthritis drug RoActemra have hit another hurdle. NICE’s independent appraisal committee has …

FDA approves Roche’s Actemra

January 11, 2010
Sales and Marketing Actemra, RoActemra, Roche, US, rheumatoid arthritis

Roche’s Actemra has been approved in the US for the treatment of moderately to severely active rheumatoid arthritis (RA) and …


NICE still saying ‘no’ to Roche’s RoActemra

December 17, 2009
Sales and Marketing NICE, RoActemra, Roche

Roche will have to present a stronger case for arthritis drug RoActemra in order to gain approval, according to NICE. …

RoActemra approved in Europe

January 29, 2009
Sales and Marketing RoActemra, Roche

The European Commission has approved Roche's RoActemra as a treatment for rheumatoid arthritis. Schering-Plough's Remicade, Wyeth's Enbrel and Abbott's Humira …

Latest content